Program overview
Context
Indication: Squamous Cell Carcinoma of Head and Neck
Mechanism: Unknown
Modality: Unknown
Sponsor: Calliditas Therapeutics Suisse SA
Setanaxib is flagged as low signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: Squamous Cell Carcinoma of Head and Neck
Mechanism: Unknown
Modality: Unknown
Sponsor: Calliditas Therapeutics Suisse SA
Registry: 0/5
Timeline: 0/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 1/5
https://clinicaltrials.gov/study/NCT05323656
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT05323656 | Low Signal (COMPLETED) | None | Low Signal | rare_population_signal | strict_eligibility_signal |